Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 5:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 152 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Painful Diabetic Neuropathy Clear all
Completed Phase 2 Interventional Results available

Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain

NCT04688671
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain, Diabetic Peripheral Neuropathy
Interventions
ETX-018810, Placebo
Drug
Lead sponsor
Eliem Therapeutics (UK) Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
22
States / cities
Mobile, Alabama • Phoenix, Arizona • Fresno, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 9, 2026, 5:08 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain

NCT04455633
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy, Diabetes
Interventions
LX9211, LX9211 Matching Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
44
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 9, 2026, 5:08 PM EDT
Completed Phase 2 Interventional

IMX-150 Cream for Diabetic Neuropathy

NCT00641953
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
IMX-150, Placebo
Drug
Lead sponsor
Procris Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Brooksville, Florida • Jupiter, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2008 · Synced Oct 9, 2026, 5:08 PM EDT
Recruiting Phase 3 Interventional

Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy

NCT07231419
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Suzetrigine, Placebo (matched to SUZ)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
75
States / cities
Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 9, 2026, 5:08 PM EDT
Completed Phase 2 Interventional Results available

A Safety Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Painful Diabetic Neuropathy

NCT02355158
View directory record Official record
Conditions
Painful Diabetic Neuropathy, Diabetes
Interventions
clonidine hydrochloride topical gel, 0.1%
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 85 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
20
States / cities
Phoenix, Arizona • Santa Monica, California • Walnut Creek, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 9, 2026, 5:08 PM EDT
Not listed Phase 2 Interventional

Using Cannabidiol to Treat Diabetic Peripheral Neuropathy of the Feet

NCT04679545
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
CBD, Placebo
Drug
Lead sponsor
Pure Green
Industry
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bloomfield Township, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 9, 2026, 5:08 PM EDT
Completed Not applicable Interventional

Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMo™ Component Training

NCT05573685
View directory record Official record
Conditions
Rheumatoid Arthritis, Diabetic Neuropathy, Fibromyalgia, Irritable Bowel Syndrome
Interventions
DiNaMo Study App, Placebo App
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 9, 2026, 5:08 PM EDT
Terminated Phase 2 Interventional

[S,S]-Reboxetine Long Term Safety Study In Chronic Painful Diabetic Peripheral Neuropathy.

NCT00348894
View directory record Official record
Conditions
Pain
Interventions
[S,S]-Reboxetine, Any
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2011 · Synced Oct 9, 2026, 5:08 PM EDT
Completed Phase 4 Interventional

A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions

NCT00904202
View directory record Official record
Conditions
Postherpetic Neuralgia, Diabetic Neuropathy, Complex Regional Pain Syndrome, Carpal Tunnel Syndrome, HIV Neuropathy, Idiopathic Sensory Neuropathy, Peripheral Neuropathy
Interventions
Placebo Capsules + Placebo Patch, Placebo capsules + Lidoderm®, Gabapentin + Placebo, Gabapentin + Lidoderm®, Gabapentin 300 mg capsules 1800 mg/day + placebo patch, Gabapentin 1800 mg/day + Lidoderm patch
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
7
States / cities
Birmingham, Alabama • Hueytown, Alabama • Phoenix, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 9, 2026, 5:08 PM EDT
Active, not recruiting Not applicable Interventional

Pain and Neurological Function Improvements With 10 kHz Spinal Cord Stimulation Treatment of Painful Diabetic Neuropathy

NCT05777317
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
10 kHz SCS, CMM alone
Device · Other
Lead sponsor
Nevro Corp
Industry
Eligibility
22 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Medford, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 9, 2026, 5:08 PM EDT
Completed Not applicable Interventional Results available

Comparison of 10 kHz SCS Combined With CMM to CMM Alone in the Treatment of Neuropathic Limb Pain

NCT03228420
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
Senza HF10 Therapy, CMM
Device · Other
Lead sponsor
Nevro Corp
Industry
Eligibility
22 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
4
States / cities
Bradenton, Florida • Stockbridge, Georgia • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 9, 2026, 5:08 PM EDT
Completed Phase 2 Interventional

The Use of a Water Soluble Under the Tongue (Sublingual) CBD Tablet for Treating Pain Associated With Diabetic Peripheral Neuropathy

NCT04088929
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
CBD
Drug
Lead sponsor
Pure Green
Industry
Eligibility
21 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Sterling Heights, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 9, 2026, 5:08 PM EDT
Terminated Phase 4 Interventional Results available

Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy

NCT00619983
View directory record Official record
Conditions
Diabetic Neuropathic Pain, Chronic Low Back Pain
Interventions
donepezil, duloxetine, donepezil 2.5 mg and duloxetine 30mg, placebo, gabapentin
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 9, 2026, 5:08 PM EDT
Terminated Not applicable Interventional

Effect of Holofiber Socks and Bedding on Pain and Quality of Sleep in Subjects With Chronic Foot Pain

NCT00458497
View directory record Official record
Conditions
Diabetic Neuropathy, Arthritis, Peripheral Arterial Disease, Plantar Fasciitis
Interventions
Holofiber fabric, PET fabric
Device
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2010 · Synced Oct 9, 2026, 5:08 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA

NCT05754190
View directory record Official record
Conditions
Chronic Pain, Acute Pain, Post Operative Pain, Fibromyalgia, Primary, Fibromyalgia, Secondary, Fibromyalgia, Irritable Bowel Syndrome, Chronic Headache Disorder, Chronic Migraine, Chronic Pelvic Pain Syndrome, Temporomandibular Joint Disorders, Endometriosis-related Pain, Arthritis, Chronic Low-back Pain, Failed Back Surgery Syndrome, Post Herpetic Neuralgia, Neuropathic Pain, Painful Diabetic Neuropathy, Painful Bladder Syndrome, Trauma-related Wound, Trauma, Multiple, Chronic Pain Syndrome, Chronic Shoulder Pain
Interventions
SOMA pain manager smartphone application
Device
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 9, 2026, 5:08 PM EDT
Completed Phase 3 Interventional Results available

Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy

NCT01057693
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
pregabalin (Lyrica), Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
633 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
150
States / cities
Birmingham, Alabama • Northport, Alabama • Gilbert, Arizona + 120 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 9, 2026, 5:08 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)

NCT00592904
View directory record Official record
Conditions
Neuralgia
Interventions
E2007
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 9, 2026, 5:08 PM EDT
Active, not recruiting Not applicable Interventional

Optimization of NIBS for Diabetic Neuropathy Neuropathic Pain

NCT03625752
View directory record Official record
Conditions
Diabetic Neuropathies, Chronic Pain
Interventions
Active Comparator: Active tDCS + Active TUS, Sham
Device
Lead sponsor
Case Western Reserve University
Other
Eligibility
40 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 9, 2026, 5:08 PM EDT
Terminated Phase 2 Interventional Results available

A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy

NCT01087203
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Tanezumab, placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
48
States / cities
Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 9, 2026, 5:08 PM EDT
Withdrawn Not applicable Interventional

Exercise Induced Hypoalgesia Diabetes

NCT05296642
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy, Diabetic Peripheral Neuropathic Pain
Interventions
Moderate Cycling, Personalized Tourniquet System
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 9, 2026, 5:08 PM EDT
Completed Phase 4 Interventional

Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy

NCT00159679
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
30
States / cities
Hot Springs, Arkansas • La Jolla, California • Torrance, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 9, 2026, 5:08 PM EDT
Completed Phase 2 Interventional Results available

Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves

NCT01939366
View directory record Official record
Conditions
Chronic Pain, Diabetic Neuropathies, Diabetes Mellitus
Interventions
Cebranopadol 100 µg, Cebranopadol 300 µg, Cebranopadol 600 µg, Pregabalin, Matching Placebo
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
15
States / cities
Mesa, Arizona • Garden Grove, California • Laguna Hills, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 9, 2026, 5:08 PM EDT
Completed Phase 4 Interventional

Safety of Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy

NCT00159731
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
29
States / cities
Hot Springs, Arkansas • La Jolla, California • Torrance, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 9, 2026, 5:08 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)

NCT01533428
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy, Pain
Interventions
Capsaicin 8%, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
29
States / cities
Anniston, Alabama • Fresno, California • Long Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 9, 2026, 5:08 PM EDT